Royalty Pharma plc (NASDAQ:RPRX) completed a $2 billion senior notes offering in September 2025, enhancing its ability to acquire long-duration royalty assets and strengthen its capital structure. The company has seen a 20% increase in portfolio receipts in Q2 2025, targeting $4.7 billion in receipts by 2030. Royalty Pharma plc remains a top choice for long-term growth, particularly in oncology, with a recent $2 billion funding deal with Revolution Medicines. Analysts are bullish on RPRX, with TD Cowen reaffirming a buy rating and a $42 price target. Consider potential AI stocks for greater upside.

Read more at Yahoo Finance: Royalty Pharma plc (RPRX) Completes $2B Senior Notes Offering, Strengthens Capital for Growth